Measuring Lactation Initiation After Early Postpartum Injectable Progestin (DMPA) Use Among Women in Dhanusha District of Nepal: A Pilot Study
NCT ID: NCT06816901
Last Updated: 2025-09-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
40 participants
INTERVENTIONAL
2025-03-26
2025-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Depot-medroxy Progesterone Acetate Injectable Contraceptives in Lactating Women 1st Week Versus 6 Week Postpartum Initiation
NCT06100783
Timing of Postpartum Depot Medroxyprogesterone Acetate Administration on Breastfeeding, Contraceptive Continuation, and Depression
NCT01463202
Immediate Postpartum Contraceptive Implant Placement and Breastfeeding Success in Women at Risk for Low Milk Supply: A Non-inferiority Trial
NCT02866279
Acceptability & Tolerance of Immediate Versus Delayed Postpartum Contraceptive Implant
NCT03353012
Breastfeeding and Oral Contraceptives: a Randomized, Controlled Trial
NCT01465022
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The investigators will conduct a pilot study among 40 birthing people who deliver a singleton, healthy, term infant; intend to feed their infant human milk (breastfeed) exclusively for at least 6 months; and plan to use DMPA for postpartum contraception. Participants will be administered DMPA within 48 hours after birth and will be followed for 12 weeks postpartum. Time to lactogenesis, the proportion of participants exclusive feed their infant human milk at 12 weeks, any lactation and infant growth through 12 weeks will be measured. We will analyze time to onset of lactogenesis the proportion of participants exclusively feeding human milk at 12 weeks.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
HEALTH_SERVICES_RESEARCH
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention
Initiation of injectable depo medroxyprogesterone acetate (DMPA) within 48 hours of birth
Depo Medroxyprogesterone acetate
Initiation of injectable depo medroxyprogesterone acetate (DMPA) contraception within 48 hours after birth
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Depo Medroxyprogesterone acetate
Initiation of injectable depo medroxyprogesterone acetate (DMPA) contraception within 48 hours after birth
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Had a vaginal or cesarean delivery of a singleton full-term infant within the past 48 hours
* Not yet undergone lactogenesis
* Desire to use DMPA as a method of postpartum contraception
Exclusion Criteria
* Do not intend to exclusively feed infant own human milk for 6 months
* Do not have access to a telephone
* Any medical contraindication to DMPA
* Any contraindication to human milk feeding for their infant
* History of breast surgery (augmentation or reduction)
* Infant with a major congenital anomaly (will be excluded due to unique challenges with feeding in these populations)
18 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Center for Research on Environment, Health and Population Activities
OTHER
University of California, San Diego
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sarah Averbach, MD MAS
Associate Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sarah Averbach, MD, MAS
Role: PRINCIPAL_INVESTIGATOR
University of California, San Diego
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Provincial Hospital Janakpur of Dhanusha district
Janakpur Dham, Dhanusha District, Nepal
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
811161
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.